4507 On Other Exchanges
4507 is not on other exchanges.

shionogi & co ltd (4507) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for SHIONOGI & CO LTD (4507)

Related News

No related news articles were found.

shionogi & co ltd (4507) Related Businessweek News

No Related Businessweek News Found

shionogi & co ltd (4507) Details

Shionogi & Co., Ltd. engages in the research, development, manufacture, and marketing of pharmaceuticals, diagnostic reagents, medical devices, etc. in Japan and internationally. It primarily focuses on prescription drugs, OTC drugs, and diagnostic reagents and devices. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.

5,896 Employees
Last Reported Date: 06/23/16
Founded in 1878

shionogi & co ltd (4507) Top Compensated Officers

Chief Executive Officer, President and Repres...
Total Annual Compensation: ¥129.0M
Compensation as of Fiscal Year 2016.

shionogi & co ltd (4507) Key Developments

Shionogi & Astellas To Sell Its Drug Brands

Astellas Pharma, Inc. (TSE:4503) and Shionogi & Co., Ltd. (TSE:4507) are looking to sell off drug brands in order to raise billions for the development of new moneymakers. Shionogi is moving to sell treatments for infectious diseases, gastrointestinal ailments and other conditions. Astellas could receive up to ?¥50 billion by divesting several drugs, possibly including ulcer treatment Gaster. Astellas seeks to decide on the buyers in the coming months.

Shionogi Announces Acceptance of New Drug Application in the U.S. for Naldemedine for the Treatment of Opioid-Induced Constipation

Shionogi announced that the New Drug Application (NDA) submitted in the U.S. for naldemedine, a once-daily, oral 0.2 mg tablet, has been accepted for review. In the U.S., the proposed indication is for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain (CNCP). The target action date under the Prescription Drug User Fee Act (PDUFA) is March 23, 2017. The company also submitted an NDA in Japan on March 30, 2016 for the proposed indication of the treatment of OIC in adult patients.

Shionogi & Co., Ltd., Annual General Meeting, Jun 23, 2016

Shionogi & Co., Ltd., Annual General Meeting, Jun 23, 2016, at 10:00 Tokyo Standard Time. Location: Herbis hall, 5-25 Umeda 2 Chome Kita-ku, Osaka 530-001 Japan Agenda: To discuss and consider the consolidated and financial statements and the non consolidated financial statements for the year ended March 31, 2016; to approve appropriation of surplus; to elect six directors; and to elect two corporate auditors.


The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

4507 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4507.
View Industry Companies

Industry Analysis


Industry Average

Valuation 4507 Industry Range
Price/Earnings 28.4x
Price/Sales 6.0x
Price/Book 3.7x
Price/Cash Flow 30.2x
TEV/Sales 5.8x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact SHIONOGI & CO LTD, please visit www.shionogi.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.